From: Validation of a blood protein signature for non-small cell lung cancer
Characteristic | Training (n = 363) | UHH validation (n = 138) | EDRN validation (n = 135) | |||
---|---|---|---|---|---|---|
 | Case | Control | Case | Control | Case | Control |
No. subjects | 94 | 269 | 111 | 27 | 63 | 72 |
Median age (years) | 69 | 57 | 62 | 58 | 68 | 71 |
Interquartile range | 63-74 | 52-64 | 54-70 | 51-71 | 62-74 | 66-76 |
Gender | Â | Â | Â | Â | Â | Â |
Male | 42 | 126 | 70 | 13 | 36 | 39 |
Female | 52 | 143 | 41 | 14 | 27 | 33 |
Median pack-years* | 40 | 40 | 35 | 30 | 60 | 38 |
Interquartile range | 23-57 | 20-56 | 20-50 | 18-43 | 40-76 | 34-60 |
Histopathology/Stage | Â | Â | Â | Â | Â | Â |
Adenocarcinoma | 64 | Â | 55 | Â | 38 | Â |
I | 27 | Â | 19 | Â | 24 | Â |
II | 7 | Â | 16 | Â | 5 | Â |
III | 19 | Â | 20 | Â | 7 | Â |
IV | 11 | Â | 0 | Â | 2 | Â |
Squamous cell | 30 | Â | 56 | Â | 25 | Â |
I | 11 | Â | 20 | Â | 14 | Â |
II | 5 | Â | 16 | Â | 4 | Â |
III | 12 | Â | 20 | Â | 3 | Â |
IV | 2 | Â | 0 | Â | 4 | Â |
Benign nodule | Â | 122 | Â | 27 | Â | 20 |